Tenaya Therapeutics Statistics
Total Valuation
TNYA has a market cap or net worth of $234.77 million. The enterprise value is $189.99 million.
Important Dates
The last earnings date was Monday, November 10, 2025, before market open.
| Earnings Date | Nov 10, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
TNYA has 166.51 million shares outstanding. The number of shares has increased by 59.81% in one year.
| Current Share Class | 166.51M |
| Shares Outstanding | 166.51M |
| Shares Change (YoY) | +59.81% |
| Shares Change (QoQ) | +0.34% |
| Owned by Insiders (%) | 0.66% |
| Owned by Institutions (%) | 17.95% |
| Float | 156.01M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.79 |
| P/TBV Ratio | 2.83 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.64, with a Debt / Equity ratio of 0.14.
| Current Ratio | 4.64 |
| Quick Ratio | 4.26 |
| Debt / Equity | 0.14 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -96.44% and return on invested capital (ROIC) is -54.85%.
| Return on Equity (ROE) | -96.44% |
| Return on Assets (ROA) | -49.48% |
| Return on Invested Capital (ROIC) | -54.85% |
| Return on Capital Employed (ROCE) | -105.93% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$971,732 |
| Employee Count | 97 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -58.77% in the last 52 weeks. The beta is 3.14, so TNYA's price volatility has been higher than the market average.
| Beta (5Y) | 3.14 |
| 52-Week Price Change | -58.77% |
| 50-Day Moving Average | 1.54 |
| 200-Day Moving Average | 0.94 |
| Relative Strength Index (RSI) | 52.33 |
| Average Volume (20 Days) | 2,449,105 |
Short Selling Information
The latest short interest is 19.59 million, so 11.76% of the outstanding shares have been sold short.
| Short Interest | 19.59M |
| Short Previous Month | 18.59M |
| Short % of Shares Out | 11.76% |
| Short % of Float | 12.55% |
| Short Ratio (days to cover) | 4.70 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -97.21M |
| Pretax Income | -94.26M |
| Net Income | -94.26M |
| EBITDA | -88.51M |
| EBIT | -97.21M |
| Earnings Per Share (EPS) | -$0.72 |
Full Income Statement Balance Sheet
The company has $56.31 million in cash and $11.53 million in debt, giving a net cash position of $44.79 million or $0.27 per share.
| Cash & Cash Equivalents | 56.31M |
| Total Debt | 11.53M |
| Net Cash | 44.79M |
| Net Cash Per Share | $0.27 |
| Equity (Book Value) | 82.87M |
| Book Value Per Share | 0.51 |
| Working Capital | 48.03M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$72.71 million and capital expenditures -$755,000, giving a free cash flow of -$73.47 million.
| Operating Cash Flow | -72.71M |
| Capital Expenditures | -755,000 |
| Free Cash Flow | -73.47M |
| FCF Per Share | -$0.44 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |